Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter

Journal of Nuclear Medicine

Volumn 49, Issue 4, 2008, Pages 615-622

  Mitsuoka, Keisuke ^a   Miyoshi, Sosuke ^b   Kato, Yukio ^a   Murakami, Yoshihiro ^b   Utsumi, Rie ^a   Kubo, Yoshiyuki ^a   Noda, Akihiro ^b   Nakamura, Yukio ^c   Nishimura, Shintaro ^b   Tsuji, Akira ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Medical and Pharmacological Research Center Foundation   (Japan)

^c RIKEN BIORESOURCE CENTER   (Japan)

Author keywords

11C glycylsarcosine; Cancer detection; Dipeptide PET tracer; H+ peptide transporter; PEPT1; PEPT2; Peptide transport activity

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLYCYLSARCOSINE C 11; PEPTIDE TRANSPORTER 1; PEPTIDE TRANSPORTER 2; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER DIAGNOSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; GENE EXPRESSION; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MEDICAL TECHNOLOGY; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOACTIVITY; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; CARBON RADIOISOTOPES; CELL LINE, TUMOR; DIPEPTIDES; FLUORODEOXYGLUCOSE F18; IMMUNOHISTOCHEMISTRY; MALE; MICE; NEOPLASMS, EXPERIMENTAL; POSITRON-EMISSION TOMOGRAPHY; SYMPORTERS; TISSUE DISTRIBUTION;

EID: 42049085310     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.048231     Document Type: Article

References (33)

1. Herrera-Ruiz D, Knipp GT. Current perspectives on established and putative mammalian oligopeptide transporters. J Pharm Sci. 2003;92:691-714.
2. Daniel H. Molecular and integrative physiology of intestinal peptide transport. Annu Rev Physiol. 2004;66:361-384.
3. Sai Y, Tsuji A. Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov Today. 2004;9:712-720.
4. Rubio-Aliaga I, Daniel H. Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol Sci. 2002;23:434-440.
5. +/peptide cotransporter PEPT2 determined by three-dimensional quantitative structure-activity relationship analysis. J Med Chem. 2006;49:4286-4296.
6. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3:380-387.
7. Doring F, Walter J, Will J, et al. Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J Clin Invest. 1998;101:2761-2767.
8. Ocheltree SM, Shen H, Hu Y, Xiang J, Keep RF, Smith DE. Role of PEPT2 in the choroid plexus uptake of glycylsarcosine and 5-aminolevulinic acid: studies in wild-type and null mice. Pharm Res. 2004;21:1680-1685.
9. Schlapbach R, Fontana A. Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycin-induced apoptosis of glioma cells. Biochim Biophys Acta. 1997;1359:174-180.
10. +/dipeptide cotransport system. J Pharmacol Exp Ther. 1990;252:859-862.
11. Nakanishi T, Tamai I, Takaki A, Tsuji A. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int J Cancer. 2000;88:274-280.
12. Nakanishi T, Tamai I, Sai Y, Sasaki T, Tsuji A. Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer Res. 1997;57:4118-4122.
13. Gonzalez DE, Covitz KM, Sadee W, Mrsny RJ. An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res. 1998;58:519-525.
14. +-Peptide cotransport in the human bile duct epithelium cell line SK-ChA-1. Am J Physiol Gastrointest Liver Physiol. 2002;283:G222-G229.
15. 18F-FDG uptake. J Nucl Med. 2004;45:930-932.
16. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42:1551-1555.
17. Perumal M, Pillai RG, Barthel H, et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res. 2006;66:8558-8564.
18. 18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med. 1999;40:1367-1373.
19. 11C-methionine. J Nucl Med. 2006;47:679-688.
20. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273:23629-23632.
21. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos. 2007;35:1333-1340.
22. Kim HR, Park SW, Cho HJ, et al. Comparative gene expression profiles of intestinal transporters in mice, rats and humans. Pharmacol Res. 2007;56:224-236.
23. +/peptide cotransporter: cloning, functional expression, and chromosomal localization. J Biol Chem. 1995;270:6456-6463.
24. Lu H, Klaassen C. Tissue distribution and thyroid hormone regulation of Pept1 and Pept2 mRNA in rodents. Peptides. 2006;27:850-857.
25. 11C]Glycylsarcosine: synthesis and in vivo evaluation as a PET tracer of PepT2 transporter function in kidney of PepT2 null and wild-type mice. Bioorg Med Chem. 2005;13:2993-3001.
26. Inoue M, Terada T, Okuda M, Inui K. Regulation of human peptide transporter 1 (PEPT1) in gastric cancer cells by anticancer drugs. Cancer Lett. 2005;230:72-80.
27. 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003;30:607-611.
28. Izumi H, Torigoe T, Ishiguchi H, et al. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev. 2003;29:541-549.
29. Fei YJ, Kanai Y, Nussberger S, et al. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature. 1994;368:563-566.
30. Hara T, Bansal A, DeGrado TR. Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging. 2006;5:498-509.
31. Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27:1415-1419.
32. 18F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168:273-280.
33. +/peptide cotransporters. FEBS J. 2007;274:5905-5914.